Sector: Chemicals

Latest content

The Asia IP Elite – a shared commitment to excellence across very different markets

IAM reveals the top in-house IP teams from India, Southeast Asia and Australasia

14 December 2020

Korea’s tough selection patent inventiveness rules may be overturned

The country’s Supreme Court is expected to hand down a potentially momentous decision in the coming months

10 December 2020

China’s gene sequencing equipment champion seeks public listing amidst sprawling global patent battle

BGI and its sequencer-manufacturing subsidiary MGI Tech made over 70% of their revenue abroad last year, but face over 20 patent assertions in overseas markets

10 December 2020

Australian vaccine patent ruling shows tough new support requirements for life sciences innovators

Wyeth’s dispute with MSD underscores move towards stricter, UK-style disclosure obligations for IP rights

08 December 2020

New patent politics put US public-private partnerships under threat, says BIO’s IP chief

In an exclusive interview, Hans Sauer talks of concerns over a shift in federal strategy and argues that government research funding should not be seen as a commercial investment

03 December 2020

Top EPO opposition firms by technical areas of specialisation revealed

Detailed analysis of representatives shows that while some tend to specialise in certain technologies, others act across a wider range of IPC sections

03 December 2020

A unitary EU SPC system may be on the cards, but it will be tough to achieve

Although life sciences companies would favour such a change, there are significant obstacles standing in the way of it happening

01 December 2020

Do not expect an electronic vehicle patent boom in the UK despite 2030’s petrol and diesel car sales ban

Plans announced by British Prime Minister Boris Johnson will not change the IP reality, which is that Germany is the only serious game in town for auto in Europe

27 November 2020

US legislators move to close another “evergreening loophole” for orphan drugs

Recent reforms have made it harder to obtain regulatory exclusivity for follow-on versions of rare disease treatments

24 November 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations

19 November 2020

Unlock unlimited access to all IAM content